Notice of Intent to Sole Source Naval Health Clinic Hawaii Roche Cobas Chemistry Analyzers

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Defense Health Agency intends to negotiate on a sole source basis (IAW FAR 13.501(a), Only One Responsible Source. The proposed source is Roche Diagnostics Corporation, 9915 Hague Rd, Indianapolis, Indiana, 46256-1025.

The requirement is for a contract for the lease of two (2) Chemistry analyzers, annual off-site key operator training for each analyzer, purchase of reagents, third party quality controls (Bio-Rad), maintenance service, and consumables for Naval Health Clinic (NHCH).  One (1) clinical chemistry/immunoassay analyzer shall be for Branch Health Clinic (BHC) Makalapa, and one (1) clinical chemistry analyzer shall be for BHC Kaneohe Bay. The contracted analyzer for Makalapa shall be a single platform configuration capable of performing general chemistry, immunoassay, and screening for electrolytes, diabetes, hepatic diseases, thyroid diseases, cardiac diseases, renal diseases, and infectious diseases, as defined below. The contracted analyzer for BHC Kaneohe Bay shall be capable of performing general chemistry, and screening for electrolytes, hepatic diseases, renal diseases, and cardiac diseases.  The contracted analyzers for each clinic shall be capable of performing the tests listed below at the yearly indicated test volume. The contracted analyzers for BHC Makalapa and BHC Kaneohe Bay shall have the same test methodology to ensure accuracy of results between clinics. The contractor shall be capable of 24-hour response time. The contractor shall be available for telephone troubleshooting consultation 24 hours a day, 7 days a week, 365 days per year, except on Federal holidays. The contract shall include operator training.  The contract shall include water purifiers connected to the analyzers, its’ maintenance service, and all consumables.

BHC Makalapa Requirements:

The contracted analyzer shall be an integrated general chemistry and immunoassay analyzer providing a single footprint that provides Syphilis Antibody testing algorithm.  The contracted analyzer shall be capable of completing a minimum of 375 tests per hour. Due to space constraints, the contracted analyzer shall fit within the following dimensions: 70 inches (H) x 98 inches (W) x 32 inches (D). The contracted analyzer shall perform all the analytes at the annual estimated test volume as indicated below.

2022 ANNUAL ESTIMATED TEST VOLUME (REPORTABLE) - BHC MAKALAPA

TEST

QTY

TEST

QTY

TEST

QTY

ALBUMIN

4691

CREATININE

5592

POTASSIUM

3901

ALKP

4336

CREATINE KINASE

110

SODIUM

3896

ALT

4314

GGT

417

T3, FREE

83

AST

5338

GLUCOSE

5015

T4, FREE

1058

BICARBONATE

4002

BETA HCG

345

TOTAL PROTEIN

4292

BILIRUBIN, DIRECT

516

HDL

4099

TRIGLYCERIDES

4045

BILIRUBIN, TOTAL

4501

HBA1C

5801

TSH

4922

CALCIUM

4073

LDL

3959

UREA/BUN

5538

CHLORIDE

3895

MAGNESIUM

248

URIC ACID

313

CHOLESTEROL, TOTAL

4134

PHOSPHORUS

426

SYPHILIS SCREEN

1845

URINE CREATININE

1391

BHC Kaneohe Bay Requirements:

The contracted general chemistry analyzer shall be capable of completing a minimum of 375 tests per hour. The contracted analyzer shall fit within the following dimensions: 70 inches (H) x 58 inches (W) x 32 inches (D). The contracted analyzer shall perform all the analytes at the annual estimated test volume as indicated below.

2022 ANNUAL ESTIMATED TEST VOLUME (REPORTABLE) - BHC KANEOHE BAY

TEST

QTY

TEST

QTY

TEST

QTY

ALBUMIN

2515

CHLORIDE

2190

PHOSPHORUS

181

ALKP

2478

CHOLESTEROL, TOTAL

2166

POTASSIUM

2199

ALT

2373

CREATININE

2598

SODIUM

2190

AST

2594

CREATINE KINASE

100

TOTAL PROTEIN

2357

BICARBONATE

2190

GGT

185

TRIGLYCERIDES

2129

BILIRUBIN, DIRECT

420

GLUCOSE

2889

UREA/BUN

2592

BILIRUBIN, TOTAL

2642

HDL

2151

URIC ACID

142

CALCIUM

2253

LDL

2090

Periods of Performance

Base:     01 October 2023 - 30 September 2024

OPT1:   01 October 2024 - 30 September 2025

OPT 2:  01 October 2025 - 30 September 2026

OPT 3:  01 October 2026 - 30 September 2027

OPT 4:  01 October 2027 - 30 September 2028

There are not set-aside restrictions for this requirement.  The intended procurement will be classified under North America Industry Classification System (NAICS) 334516.  This notice of intent is not a request for competitive proposals and no solicitation document exists for this requirement.  However, parties interested in responding to this notice will need to submit technical data sufficient to determine capability in providing the same product.  All capability statements received by the closing date of this synopsis will be considered by the Government.  A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government.  Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

If a vendor challenges the basis of this requirement, please email product capability statements (formats for submission: PDF, MS Word, or MS Excel) to Cassi Jo Newman at cassi.j.newman.civ@health.mil Closing date for challenges is no later than 0800 PDT on 05 September 2023.  No phone calls will be accepted.